Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
暂无分享,去创建一个
F. Uckun | C. Cogle | E. Wang | Tara L. Lin | P. Patel | P. Shami | E. Cull | J. Watts | A. Mims | Cynthia Lee | T. Lin
[1] F. Uckun,et al. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome , 2021, Cancers.
[2] M. Heuser,et al. Treatment for Relapsed/Refractory Acute Myeloid Leukemia , 2021, HemaSphere.
[3] M. Sadelain,et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy , 2021, Nature Reviews Immunology.
[4] M. Konopleva,et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand , 2021, Frontiers in Oncology.
[5] N. Daver,et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments , 2021, Leukemia.
[6] S. Jamal,et al. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome , 2021, Cell Reports Medicine.
[7] F. Ravandi,et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study , 2020, Blood.
[8] P. Vyas,et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter , 2020, Blood Cancer Journal.
[9] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[10] W. Blum,et al. Treating acute myeloid leukemia in the modern era: A primer , 2020, Cancer.
[11] Jihye Kim,et al. Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection , 2020, International Journal of Obesity.
[12] H. Einsele,et al. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types , 2020, Cancer.
[13] Amber Dance. What is a cytokine storm? , 2020 .
[14] M. Konopleva,et al. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. , 2020, Cancer discovery.
[15] C. Dinardo,et al. How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.
[16] E. Elez,et al. Cytokine release syndrome. Reviewing a new entity in the intensive care unit. , 2019, Medicina intensiva.
[17] Catherine Lai,et al. Recent drug approvals for acute myeloid leukemia , 2019, Journal of Hematology & Oncology.
[18] D. Jablonski,et al. Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques , 2019, Immunology.
[19] W. Blum,et al. Progress in the problem of relapsed or refractory acute myeloid leukemia , 2019, Current opinion in hematology.
[20] F. Ferrara,et al. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia , 2019, Cancers.
[21] I. Aldoss,et al. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment , 2019, Current Oncology Reports.
[22] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] W. Murphy,et al. Obesity as an immune‐modifying factor in cancer immunotherapy , 2018, Journal of leukocyte biology.
[24] J. Gross,et al. Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release , 2018, Immunology.
[25] M. Konopleva,et al. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.
[26] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[27] R. Schlenk,et al. Relapsed/refractory acute myeloid leukemia: any progress? , 2017, Current opinion in oncology.
[28] J. Cortes,et al. Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.
[29] J. Blankenship,et al. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer , 2016, Molecular Cancer Therapeutics.
[30] M. Weiss,et al. Immunotherapy in acute myeloid leukemia , 2015, Cancer.
[31] C. Sentman,et al. Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.
[32] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[33] S. Jang,et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia , 2012, Annals of Hematology.
[34] J. Margolick,et al. Multisite Comparison of High-Sensitivity Multiplex Cytokine Assays , 2011, Clinical and Vaccine Immunology.
[35] Peter Lloyd,et al. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. , 2009, Current opinion in biotechnology.
[36] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[37] K. Mitani. [Myelodysplastic syndrome]. , 2020, Nihon rinsho. Japanese journal of clinical medicine.
[38] J. Dutcher,et al. Managing toxicities of high-dose interleukin-2. , 2002, Oncology.
[39] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.
[40] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.